Research on how cancer spreads through the body. Covers metastasis monitoring, bone metastasis, and nanoparticle treatments.
A new immunotherapy combination shows durable clinical benefits in patients with microsatellite instability-high (MSI-H) metastatic colorectal cancer, with 60% objective response rate and 84% of patients experiencing tumour shrinkage. The treatment is also well-tolerated, with manageable side effects.
A large comparison study found that radiotherapy to the prostate improved failure-free survival but not overall survival in men with newly diagnosed metastatic prostate cancer and a low burden of disease. The treatment was well-tolerated, with only modest side effects.
A large study found that drugs approved for women's breast cancer are also effective and well-tolerated in men. Men with metastatic breast cancer received similar treatments to women, including hormonal therapy and chemotherapy, with similar outcomes.
Atezolizumab, an antibody targeting PD-L1, improved survival in metastatic triple negative breast cancer patients by 20%, particularly those with PD-L1 positive tumors. The combination therapy also reduced disease worsening and death risk by 38% in PD-L1 positive subgroup
A new statistical method estimates the short- and long-term risk of recurrence for hormone receptor-positive and HR-negative breast cancers in US women. The study found that while HR-positive breast cancer has a lower risk of progression to metastatic disease soon after diagnosis, the risk persists for several years.
Neutrophils isolated from bone marrow of mouse models and patients with early stage tumors exhibit increased spontaneous migration to tissues and promote tumor cell seeding. These neutrophils lack immunosuppressive characteristics, but display potent ability to spontaneously migrate and facilitate metastasis.
Researchers at Mount Sinai have discovered a new way to determine whether breast cancer cells are dormant or soon to turn deadly. Patients with high levels of the NR2F1 protein in their bone marrow are less likely to develop metastatic cancer, allowing for more targeted treatment and improved survival rates.
A new report reveals a protein, deltaNp63, that directs myeloid-derived immunosuppressor cells (MDSCs) to the primary tumor and metastatic sites, promoting tumor growth and metastasis. Blocking deltaNp63 or MDSCs reduced tumor growth and metastasis in a mouse model of triple-negative breast cancer.
Patients with metastatic non-small cell lung cancer (NSCLC) treated at academic centers had higher 2-year survival rates than those treated at community-based centers. The study found significant differences in survival outcomes based on facility type, histology, and molecular profile.
A new study suggests targeting collagen XIII could suppress breast cancer metastasis by enhancing anoikis resistance in cancer cells. Researchers found that collagen XIII expression is significantly higher in cancerous human breast tissue and necessary for metastasis in mouse models.
Researchers at Cold Spring Harbor Laboratory found that sustained lung inflammation can awaken dormant breast and prostate cancer cells, leading to metastasis. A new antibody approach may block this signaling pathway, preventing cancer recurrence.
Researchers at UC Riverside have discovered a way to target migrating cancer cells, responsible for tumor metastases, using novel agents 135H11 and 135H12. These potent agents can block EphA2, an oncogene that spreads cancer, preventing cell migration and degradation.
Researchers discovered that driver gene mutations are remarkably similar across different metastases from the same patient, offering hope for successful targeted therapies. This finding suggests that single biopsies can capture essential information for therapeutic decision-making.
Scientists at the Medical University of South Carolina discovered that over-expression of VRK1 actually slows down cancer cell migration and invasion, but enables cells to form colonies under 3D conditions. High levels of VRK1 are associated with aggressive breast cancers and poor prognoses in patients with metastatic breast cancer.
Phase 1 and phase 2 clinical trials of entrectinib in ROS1-positive non-small cell lung cancer demonstrated a response rate of 77.4 percent and median duration of response of 24.6 months. Entrectinib also showed competitive results in patients with brain metastases and poor prognosis
Researchers at UCLA have created a quick and effective mechanism to measure how circulating tumor cells perform functions that drive disease, such as producing proteins that degrade tissue. The new approach enables scientists to understand how tumor cells act, rather than just what they are made from.
A new study identified 'signposts' on cancer cells that can help the immune system recognize and kill them, potentially leading to higher recovery rates. The findings suggest a highly personalized approach to immunotherapy could improve treatment outcomes.
Scientists from the University of Luxembourg have identified a molecular mechanism responsible for colon cancer cell spread and metastasis. A small molecule cluster, miR-371~373, was found to regulate colon cancer metastasis in aggressive, fast-growing cancer cells. Reactivation of this cluster slowed down metastatic cell growth.
Researchers found that rapidly spreading ovarian cancer cells recruit CAFs to accelerate cancer proliferation and spread by enhancing energy sources. Blocking glycogen mobilization could be a therapeutic strategy for reducing tumor dissemination.
A study found that common mutations drive the spread of cancer in individual patients, suggesting a key understanding of how cancers metastasize. The research also identified passenger mutations that are less likely to play a critical role in cancer development.
A new study analyzing 76 untreated metastases from 20 patients found that different metastatic lesions share the same driver gene mutations. The findings suggest that a biopsy of a single metastatic lesion could provide sufficient information for treatment decisions.
Researchers have discovered a specific protein, FABP5, that promotes processes associated with cancer aggressiveness, including cell growth, invasiveness, survival, and inflammation. Understanding the molecular pathways of this protein could lead to finding more effective therapeutic targets for prostate and breast cancers.
Researchers aim to develop a blood test to detect and track metastatic melanoma by analyzing circulating tumor DNA in the bloodstream, promising a more precise, individualized, sensitive, and quantifiable approach than current imaging tests.
Researchers discovered a previously unseen 'ecosystem' in advanced breast cancer, where primary tumors emit signals to halt secondary tumor growth. The study found that activating the immune response can freeze secondary cancers, offering new hope for living with advanced breast cancer.
Researchers found that inflammatory response triggered by primary breast cancer prevents tumor cells from growing in distant organs. Inhibitors of interleukin-1β, such as canakinumab, are being tested in clinical trials for potential benefits in preventing metastatic growth.
A clinical trial found that combination immunotherapy reduced melanoma brain metastases by 26% in 94 patients. The treatment, combining checkpoint inhibitors ipilimumab and nivolumab, also showed durable responses with 59.5% of patients remaining progression-free at nine months.
A University of Colorado Cancer Center study reveals that inhibiting the action of lysosomes can efficiently kill metastatic cancer cells. Researchers found that the level of a protein called ID4 predicts which cancer patients will benefit most from treatment with chloroquine.
The EMBRACA trial shows that talazoparib provides a significant clinical benefit to patients with metastatic breast cancer and BRCA mutations. The study found that talazoparib improved progression-free survival, quality-of-life measures, and overall response rates compared to chemotherapy.
A new study suggests that cancer treatment should be viewed as a game where physicians can exploit their knowledge of the cancer's evolutionary dynamics to develop flexible strategic treatment plans. By continuously adjusting drugs and doses, physicians can delay or prevent cancer progression caused by resistance.
A team of researchers has confirmed that healthy tumor hybrid cells contribute to metastasis by forming spontaneously in live animals. Gene expression profiles show a mix of genes from both cell types, aiding metastatic cells in survival and potential groundwork for other tumor cells.
Researchers investigate how a group of cells breaks off from a colony, leading to large-scale metastasis. Mechanical engineer Amit Pathak aims to understand the mechanisms behind disease pathways and fundamental cell behavior.
Researchers developed a molecular probe to detect cancer stem cells in their native environment. The AlDeSense probe illuminates these cells, allowing them to be identified, tracked, and studied in live mice.
Scientists at MD Anderson Cancer Center have engineered a system allowing microscopic monitoring and imaging of cancer in mice, enabling better understanding and treatment of bone metastasis. The model reveals how cancer cells interact with bone and bone resident cells over time, providing insights into the disease's progression.
Medical researchers from MSU propose a new targeted cancer therapy by increasing the activity of wild-type p53, which supports genetic stability and prevents malignant tumor formation. The study reveals that p53 also regulates metastasis formation through various programmed cell death pathways.
A new mouse model has been developed to study bone metastasis, allowing researchers to inject a large number of cancer cells without causing death. The model enables the detection of bone metastasis in the hind limbs with high efficiency and provides insights into cancer cell dormancy and reactivation.
Checkpoint inhibitors have been shown to double median survival and more than double four-year survival rates for patients with melanoma brain metastases. The study analyzed data from over 1,500 cancer programs, revealing a significant improvement in overall survival.
Checkpoint inhibitors improve median and four-year overall survival rates for melanoma brain metastasis patients by 1.4- and 1.5-fold, respectively, according to a national cohort study published in Cancer Immunology Research.
A Phase 1b clinical trial has demonstrated that the combination of tucatinib and T-DM1 can control median 8.2 months in heavily pretreated HER2-positive breast cancer patients, with 48% response rate. The drug also shows efficacy against brain metastases, a major cause of mortality from the disease.
A University of Colorado Cancer Center study found that brain metastases are a common occurrence in stage IV ROS1-positive non-small cell lung cancer. The study also showed that patients with ROS1 mutations had similar progression-free survival rates as ALK patients when treated with crizotinib, but with a higher risk of brain metastas...
Researchers discovered that pancreatic cancer cells' ability to alter their characteristics and shape affects where metastases form. The presence of E-cadherin protein controls this process, with its absence leading to lung metastases but not liver metastases.
A new computational method, MACHINA, has been developed to track the spread of cancer cells from one part of the body to another. The algorithm integrates DNA sequence data with information on where cells are located in the body, yielding a clearer picture of cancer migration histories than previous studies.
A new study finds that enzalutamide significantly lowers the risk of metastasis or death in men with non-metastatic castrate-resistant prostate cancer, delaying cancer re-appearance by almost two years. The drug also shows a 71% lower risk of metastasis or death compared to placebo.
PharmaMar and Chugai agree on an early termination of their license agreement for Zepsyre in Japan, allowing PharmaMar to regain rights to the compound. PharmaMar will receive €3,000,000 from Chugai and can now pursue new partnerships for the drug.
A new regulatory axis involving the transcription factor Prox1 has been revealed to negatively regulate MMP14 protein levels, which plays a significant role in cancer progression and metastasis. This discovery provides new insights into the mechanisms governing MMP14's function in physiological processes such as wound healing.
A new smart probe developed by Tel Aviv University researchers can detect and visualize individual cancer cells in real-time, allowing surgeons to target specific tumor locations. The probe uses near-infrared technology to identify overproduced enzymes in cancer cells, guiding precise removal of malignant tissue.
A University of Colorado Cancer Center study shows that combining radiosurgery with immunotherapy, especially PD-1 inhibitors, can significantly improve cancer control and overall survival in melanoma patients. The study found that patients treated with anti-PD-1 therapies had a median brain metastasis-free survival of not reached, whe...
University of Alberta researchers discovered 11 genes that play essential roles in cancer cell metastasis, enabling the blockage of over 99.5% of cancer metastasis in living cells. The study suggests potential therapeutic targets for preventing cancer spread.
A study led by CNIO researchers shows that silibinin reduces brain metastasis lesions in mice and patients, targeting the tumor microenvironment. The treatment has shown encouraging results, with 75% of patients reacting positively and a 15.5-month average survival rate
The ALEX trial results show alectinib achieving a median progression-free survival of 34.8 months compared to 10.9 months for crizotinib in ALK-positive non-small cell lung cancer patients. Alectinib also demonstrated an improved overall response rate and fewer side effects than crizotinib.
Weichselbaum, Professor and Chairman of Radiation and Cellular Oncology at the University of Chicago, has made significant contributions to understanding oligometastasis. His work on curing tumors through surgery or radiation therapy has been supported by several studies demonstrating successful treatments.
Researchers from University of Pennsylvania develop a mathematical model to understand the dynamics of cancer growth and spread. The study suggests that mutations leading to metastasis often arise early in tumor history, contrary to previous observations.
A new software tool called the automated bone scan index (aBSI) has been shown to be both accurate and speedy in calculating how extensively bones have been infiltrated by prostate cancer. The aBSI technology provided prognostic information about patient outcomes, including survival time and symptom progression.
Researchers have discovered that the act of reading histone modifications leads to the modification of an oncoprotein called TRIM24 with a small protein tag called SUMO. This discovery suggests new ways to inhibit metastasis in cancer cells by targeting TRIM24's interactions with histones.
Scientists have discovered a new compound, metarrestin, that significantly reduces metastasis in human prostate, breast and pancreatic cancer in mice. The compound was found to blow up the complex marker PNC, which indicates cancer cells' ability to spread.
Researchers identified metarrestin as a compound that stops tumor metastasis in animal models. The compound effectively blocks the spread of pancreatic and other cancers, with mice treated with metarrestin having fewer tumors and living longer.
Researchers developed a novel inertial cell focusing and sorting microfluidic device with a wavy channel structure, achieving size-based separation of target cells. The device offers high-throughput, low-energy consumption, and simplified setup, making it suitable for practical biomedical applications.
Researchers have identified a key protein, MIP-1β, that enables ovarian cancer cells to spread through the peritoneal cavity by making mesothelial cells sticky. This discovery could lead to new therapies targeting this protein and its related adhesion protein P-selectin.
Researchers at the University of Montreal have discovered a protein, AXL, that influences the occurrence of metastasis in HER2-positive breast cancers. The study found that reducing AXL levels improves survival rates, and an AXL-inhibiting drug therapy has shown promise in preventing metastases.
Scientists have identified a critical function of the PDK1 signaling pathway in cancer cells, which regulates the formation of a three-protein complex that facilitates purine production and thiamine synthesis. This discovery may lead to new insights into the causes of metastasis and potential ways to prevent it.
A study by UNC Lineberger Comprehensive Cancer Center researchers found that parenting concerns significantly impact the quality of life of mothers with late-stage cancer. The study surveyed 224 mothers and discovered that these concerns contribute as much to their emotional well-being as day-to-day physical functioning does.